Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: A randomized, double-blind study in urban Asia

World Journal of Gastroenterology

Volumn 11, Issue 20, 2005, Pages 3091-3098

  Fock, Kwong Ming ^a   Teo, E K ^a   Ang, T L ^a   Chua, T S ^a   Ng, T M ^a   Tan, Y L ^a  

^a CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

New proton pump inhibitors; Non erosive esophageal reflux disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ESOMEPRAZOLE; MYLANTA; RABEPRAZOLE;

ADULT; ARTICLE; ASIA; CIRCADIAN RHYTHM; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEADACHE; HEARTBURN; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URBAN AREA;

EID: 20344376221     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i20.3091     Document Type: Article

References (25)

1. Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98 (Suppl): S2-S7
2. Damiano A, Siddique R, Xu X, Johanson J, Sloan S. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. Dig Dis Sci 2003; 44: 657-662
3. Holtmann G. Reflux disease: the disorder of the third millennium. Eur J Gastroenterol Hepatol 2001; 13: S5-11
4. Ho KY, Kang JY, Seow A. Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. Am J Gastroenterol 1998; 93: 1816-1822
5. Wong WM, Lai KC, Lam KF, Hui WM, Hu WH, Lam CL, Xia HH, Huang JQ, Chan CK, Lam SK, Wong BC. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther 2003; 18: 595-604
6. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Nonerosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17: 537-545
7. Goh KL, Chang CS, Fock KM, Ke M, Park HJ, Lam SK. Gastrooesophageal reflux disease in Asia. J Gastroenterol Hepatol 2000; 15: 230-238
8. Fock KM, Talley N, Hunt R, Fass R, Nandurkar S, Lam SK, Goh KL, Sollano J. Report of the Asia-Pacific Consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol 2004; 19: 357-367
9. Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 479-485
10. Galmiche JP, Zerbib F, Ducrottè P, Fournet J, Rampal P, Avasthy N, Humphries TJ. Decreasing oesophageal acid exposure patients with GERD: a comparison of rabeprazole and omeprazole. Aliment Pharmacol Ther 2001; 15: 1343-1350
11. Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: A randomized placebo-controlled trial. Am J Gastroenterol 2002; 97: 1332-1339
12. Cloud ML, Enas E, Humphries TJ, Bassion S. The Rabeprazole Study Group. Rabeprazole in treatment of acid peptic diseases. Results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci 1998; 43: 993-1000
13. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 49-57
14. Thjodleifsson B, Rindi G, Fiocca R, Humphries TJ, Morocutti A, Miller N, Bardhan KD. European Rabeprazole Study Group. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg of rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther 2003; 17: 343-351
15. Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D'Amico D, Hamelin B, Joelsson B. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 1249-1258
16. Lind T, Rydberg L, Kylebäck A, Jonsson A, Andersson T, Hasselgren G, Holmberg J, Rohss K. Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-867
17. Wilder-Smith CH, Rohss K, Nilsson-Pieschl C, Junghard O, Nyman L. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. Digestion 2003; 68: 184-188
18. Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002; 16: 1301-1307
19. Baisley K, Warrington S, Tejura B, Morocutti A, Miller N. Rabeprazole 20 mg compared with esomeprazole 40 mg in the control of intragastric pH in healthy volunteers. Gut 2002; 50 (Suppl 2): A63
20. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 1507-1514
21. Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, Haug K, de Groot G, van Oudvorst A, Dalvag A, Junghard O, Wiklund I. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10: 119-124
22. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: A double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997; 11: 765-773
23. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 965-973
24. Fletcher J, Wirz A, Young J, Vallance R, McColl KE. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001; 121: 775-783
25. Bytzer P, Blum A, De Herdt D, Dubois D. The Trial Investigators. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004; 20: 181-188